Overview

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

Patients with advanced HCC, refractory to atezolizumab and bevacizumab will be treated with pembrolizumab and lenvatinib. Efficacy of the combination therapy will be assessed by objective reposnse rate, progression free survival, overal survival, safety/tolerability.

Phase:

Phase 2

Details

Lead Sponsor:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators:

Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel
Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Pembrolizumab